Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
District's medical plan costs jump 13.8%; finance cites GLP‑1 drugs as a key driver
Summary
Business office reported Pleasant Valley's composite medical premium rose 13.8% this year and attributed roughly five percentage points of that increase to GLP‑1 weight‑loss and diabetes drugs (Ozempic, Wegovy, Mounjaro, Zepbound); staff described new insurer utilization criteria and potential relief if generics arrive.
The district's business office told the board medical plan costs for Pleasant Valley rose by a composite 13.8% this year, and staff said a significant share of the prescription‑drug portion of the increase was tied to GLP‑1 weight‑loss and diabetes medications.
Finance staff said the consortium's composite rate for Pleasant Valley increased 13.8%. Staff then broke down the prescription‑drug contribution: the district's prescription cost category rose from 6.8% to 13% (an increase of about seven points) and roughly 5 percentage points of the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
